It’s good news in the fight against colorectal cancer: A new test can detect the disease with a simple blood draw. But don’t cancel your colonoscopy just yet — that old standby is still more reliable ...

The Food and Drug Administration (FDA) has recently approved a blood test that can assist in the primary detection of colorectal cancer. This test could assist with prompt detection and intervention ...

In 2024, the Food and Drug Administration (FDA) approved a blood test that can screen for colorectal cancer in people older than 45 years old at average risk for the disease. Some people may skip ...

The U.S. FDA approved the PMA application for the Shield test by Guardant Health Inc., a diagnostic for colorectal cancer (CRC) that avoids some of the issues with alternative diagnostic methods.

PALO ALTO, Calif. & HONG KONG--(BUSINESS WIRE)--Mar 16, 2026-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Shield™ multi-cancer ...

Guardant Health aims to reshape how the U.S. gets screened for colorectal cancer, by claiming a groundbreaking FDA approval for a tumor-detecting blood test aimed at a population of about 120 million ...

Guidance alerting endoscopists to adjust their peripheral gaze significantly improved adenoma detection in colonoscopies — particularly for flat lesions — regardless of the endoscopist’s experience ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced another successful readout for its ECD program, which is ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding ...

Please provide your email address to receive an email when new articles are posted on . Implementing computer-aided detection for colonoscopy had “no impact” on the rate of detection for serrated ...

Findings underscore strength of Natera’s technology for early cancer detection (ECD) PROCEED-CRC has enrolled approximately 5,000 average-risk asymptomatic screening participants with blood draws ...